SCHEMBL25625540

SCHEMBL25625540

COC(=O)C[C@H](NC(=O)CN)c1cccc(C(F)(F)F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 1/20 0.46
ATM Q13315 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 2/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
FAAH O00519 1/20 0.43
HDAC1 Q13547 2/20 0.42
HDAC6 Q9UBN7 2/20 0.42
HDAC5 Q9UQL6 2/20 0.42
HDAC8 Q9BY41 1/20 0.42
CTSA P10619 2/20 0.42
GPR139 Q6DWJ6 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24036952 0.89 PNMT (0.45) PNMTATML3MBTL1SMN1; SMN2KDM4E
SCHEMBL25625086 0.88 TACR1 (0.39) LMNA
SCHEMBL24036553 0.85 THRB (0.47) MEN1POLBKMT2AGPR139
SCHEMBL25625541 0.85 GPR139 (0.46) GPR139
SCHEMBL24036950 0.84 TACR3 (0.39) L3MBTL1SMN1; SMN2MEN1POLBKMT2A
Hydrochloric Acid SCHEMBL7173937 0.84 GPR139 (0.45) GPR139
SCHEMBL24036837 0.83 ITGB3 (0.45) HTT
SCHEMBL20743557 0.83 FAAH (0.45) SMN1; SMN2MEN1LMNAPOLBHTT
SCHEMBL24036843 0.83 ITGB3 (0.35) ATML3MBTL1SMN1; SMN2
SCHEMBL25625085 0.83 THRB (0.36) LMNAPOLBCTSA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE UBE CORPORATION (JP) 2023-06-22 US disclosed
WO-2023085396-A1 PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME UBE株式会社 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE DHFR, DPYD, CYP2D6 PNMT 1176/4885ATM 2803/4885L3MBTL1 2036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.